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Background: With a complex and extremely high clinical and genetic heterogeneity, autism spectrum disorders
(ASD) are better dissected if one takes into account specific endophenotypes. Comorbidity of ASD with epilepsy
(or paroxysmal EEG) has long been described and seems to have strong genetic background. Macrocephaly also
represents a well-known endophenotype in subgroups of ASD individuals, which suggests pathogenic mechanisms
accelerating brain growth in early development and predisposing to the disorder. We attempted to estimate the
association of gene variants with neurodevelopmental disorders in patients with autism-epilepsy phenotype (AEP)
and cranial overgrowth, analyzing two genes previously reported to be associated with autism and macrocephaly.
Methods: We analyzed the coding sequences and exon-intron boundaries of GLIALCAM, encoding an IgG-like cell
adhesion protein, in 81 individuals with Autism Spectrum Disorders, either with or without comorbid epilepsy,
paroxysmal EEG and/or macrocephaly, and the PTEN gene in the subsample with macrocephaly.
Results: Among 81 individuals with ASD, 31 had concurrent macrocephaly. Head circumference, moreover, was
over the 99.7th percentile (“extreme” macrocephaly) in 6/31 (19%) patients. Whilst we detected in GLIALCAM several
single nucleotide variants without clear pathogenic effects, we found a novel PTEN heterozygous frameshift
mutation in one case with “extreme” macrocephaly, autism, intellectual disability and seizures.
Conclusions: We did not find a clear association between GLIALCAM mutations and AEP-macrocephaly comorbidity.
The identification of a novel frameshift variant of PTEN in a patient with “extreme” macrocephaly, autism, intellectual
disability and seizures, confirms this gene as a major candidate in the ASD-macrocephaly endophenotype. The
concurrence of epilepsy in the same patient also suggests that PTEN, and the downstream signaling pathway,
might deserve to be investigated in autism-epilepsy comorbidity. Working on clinical endophenotypes might be of
help to address genetic studies and establish actual causative correlations in autism-epilepsy.
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Autism spectrum disorders (ASD) are complex clinical
conditions characterized by impairment in social and
communicative functioning, and by restricted, repetitive
and stereotyped behaviors [1]. Autism is often associated
with other neurological conditions, particularly with* Correspondence: federico.sicca@fsm.unipi.it
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unless otherwise stated.seizures or paroxysmal EEG, defining a specific condi-
tion termed “Autism-Epilepsy Phenotype” (AEP) [2]. Al-
though largely multifactorial in their background, both
conditions are highly heritable and seem to have strong
genetic underpinnings [3-6]. The recent development of
next-generation sequencing techniques has heavily fos-
tered the chance to identify genes with a putative causal
role [3]. However, the polygenic/multifactorial nature of
both ASD and epilepsy, and the heterogeneity of their
phenotypes, which possibly underlie different etiologies,
hinder the ability to demonstrate actual causalities andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plex framework, an attempt at identifying clinical endo-
phenotypes could be of help to define diverse pathogenic
subgroups pinpointing different genetic etiologies. A ma-
crocephalic endophenotype has long been described,
although the significance of this feature is still far from
clear [7-10]. Recent findings indicate that cranial over-
growth in ASD appears in the first year of life suggest-
ing possible mechanisms accelerating brain growth in
early development and predisposing to autism [11-15].
We recently demonstrated that macrocephaly associated
with global somatic overgrowth may predispose to seizures
in a sample of two-hundred and six individuals with
idiopathic ASD [16]. Also, cases of extreme macroceph-
aly in ASD have been correlated to mutations in the
gene phosphatase and tensin homolog (PTEN) [17,18],
making its testing the standard genetic screening for
patients who present with autism and macrocephaly
[19,20], although mutations account for only a small
subset of the cases and have not been clearly correlated
with susceptibility to seizures in ASD [21].
Mutations in the GLIALCAM gene (HEPACAM) have
been recently identified in a spectrum of neurological
conditions associated with macrocephaly. Biallelic, auto-
somal recessively inherited mutations in GLIALCAM
were described in a proportion of the patients with the
classic phenotype of Megalencephalic leukoencephalopa-
thy with subcortical cysts (MLC2A, MIM 613925) asso-
ciated with ataxia, spasticity, and intellectual disability
[22] and no identifiable variants in the more commonly
involved MLC1 gene (MIM 605908). Interestingly, hetero-
zygous, often de novo, mutations in GLIALCAM cause
MLC2B (MIM 613926), a dominantly inherited condition
characterized by onset of macrocephaly within the first
year of life and mildly delayed motor development associ-
ated with white matter abnormalities on brain MRI
[23-25]. In MLC2B the phenotype improves after the
first year of life and head circumference in a few chil-
dren normalizes. Most patients had delayed early motor
and language development, which subsequently normal-
ized in most, although some patients had mild residual
hypotonia or clumsiness later in childhood. Intelligence
was more variable, with intellectual disability in about
half of the children, also associated with autism in a
proportion of the cases. Seizures were a comorbid fea-
ture, though usually controlled well with medication.
Brain MRI features were initially similar to those seen
in MLC2A. On follow-up, however, all patients showed
a significant improvement in the MRI changes, with loss
of white matter swelling, disappearance of cysts in some
cases, and lack of involvement of other brain regions.
The association of megalencephaly with seizures
and autism spectrum disorders in a subset of MLC2B
patients raised our interests on the role played byGLIALCAM in the ASD-macrocephaly-epilepsy endophe-
notype and prompted search for allelic variants in a subset




The sample was selected from our research database
that included all ASD children who underwent EEG re-
cordings between January 2010 and January 2013 in our
clinical unit, and whose parents gave informed consent
for collecting and storing clinical data and DNA samples
for genetic analyses (Table 1). We selected from our
database all patients with AEP and comorbid macro-
cephaly (n = 25), and a control sample of 25 consecutive
AEP individuals with normal head circumference (HC).
In addition, we have selected 31 consecutive ASD “sim-
plex” (without seizures and with normal EEG), six of
them (19%) with associated macrocephaly, in order to
assess the relative frequency of gene variants in ASD in
the absence of overt susceptibility to epilepsy. The diagno-
sis of ASD was performed in all patients according to the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV TR) criteria for
Pervasive Developmental Disorders, and confirmed, when-
ever possible, with the Autism Diagnostic Observation
Schedule-Generic (ADOS-G). History of seizures and
video-EEG recordings during awake and sleep were evalu-
ated by two independent clinicians. HC was obtained in
all children by placing a tape measure over the maximum
occipital-frontal circumference, and was plotted for refer-
ence on standard growth charts [26]. Macrocephaly was
defined when HC was over the 97th percentile, and la-
beled as “extreme” when over the 99.7th percentile [21],
corresponding to +3 standard deviations (2010 Centers for
Disease Control and Prevention growth charts) [27].
Karyotype and Fragile-X testing were performed in 76/81
(93.8%) and 77/81 (95.1%) patients, respectively and were
normal in all. CGH-array screening, performed in 15/81
(18.5%) cases, was also negative.
Genetic analyses
Total genomic DNA from peripheral blood was obtained
from patients using standard purification protocols. The
coding exons and exon-intron boundaries of GLIALCAM
(accession number NM_152722.4) were PCR amplified
using oligonucleotide primers and conditions outlined
elsewhere [22]. The PCR products were purified with Exo-
Sap (USB, Cleveland, OH) and bidirectionally sequenced
using the BigDye v3.1 chemistry (Applied Biosystems
Foster City, CA). Chromatograms were analyzed using
SeqScape Software (Life Technologies). Synonymous,
missense and splice site variations were systematically
evaluated for modifications of exonic splicing enhancers









Sample size 25 25 6 25
Gender
- M 20 (80%) 21 (84%) 4 (66.7%) 24 (96%)
- F 5 (20%) 4 (16%) 2 (33.3%) 1 (4%)
Age (years)
- range 2.9-20.8 4.0-15.7 3.0–9.9 2.4–10.0
– mean; SD 9.7; 5.2 7.6; 3.0 5.3; 2.4 5.2; 1.8
AEP subtype:
– Seizures 13 (52%) 13 (52%) – –
– EEG abnormalities without
seizures
12 (48%) 12 (48%) – –
Age at seizure onset
–range 3.0–17.9 0.4–15 – –
–mean; SD 9.2; 4.9 4.5; 4.4 – –
Type of seizures
–Focal 10/13 (76.9%) 7/13 (53.8%) – –
–Generalized 3/13 (23.1%) 4/13 (30.8%) – –
–Spasms – 2/13 (15.4%) – –
Type of EEG abnormalities
–Focal 15/22 (68.2%) 14/23 (60.9%) – –
–Multifocal 6/22 (27.3%) 9/23 (39.1%) – –
–Diffuse 1/22 (4.5%) – – –
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SIFT analysis (http://sift.jcvi.org/); Mutation Taster ana-
lysis, http://www.mutationtaster.org/; ESEfinder, http://
rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) or consen-
sus splicing sequences in order to determine the splice site
score (rulai.cshl.edu/new_alt_exon_db2/HTML/score.html
and www.fruitfly.org/seq_tools/splice.html). We also ana-
lyzed the exons and the flanking intronic regions cor-
responding to the PTEN gene (NM_000314.4) in the 31
individuals with macrocephaly. PCR reactions were per-
formed using 50 ng of genomic DNA as template and
FastStart Taq DNA Polymerase (Roche, Mannheim,
Germany). PCR products were purified and bidirection-
ally sequenced as stated above. Primers used for PTEN
mutation screening are available upon request.
Ethics statement
This study was approved by the Research Ethics Com-
mittee of the IRCCS Fondazione Stella Maris, Pisa (Italy)
in compliance with the Helsinki Declaration and local
legislation.
Results
We tested for GLIALCAM variants 81 individuals with
ASD (50 AEP and 31 ASD “simplex”), 31 of them withconcurrent macrocephaly (see Table 1 for more clinical
details). Among macrocephalic individuals, 6/31 (19%)
were labeled as “extreme”. Whilst we did not identify any
nucleotide variant with presumable pathogenic effects, we
detected several single nucleotide variants (SNV) already
reported in polymorphic databases. In particular, we
found two non-synonymous variations, already listed
in dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), namely,
p.M218V (rs10790715) and p.N324S (rs116102273). In
our group of patients, the V218 allele occurred in 75%
of the cases, whereas S324 was present in 3.10% of the
alleles, without significant correlation with phenotypic
characteristics (such as presence of macrocephaly and/
or seizures/EEG abnormalities), and in line with figures re-
ported in the Exome Variant Server polymorphic database
(http://evs.gs.washington.edu/EVS/). Both changes had a
likely benign effect upon in silico prediction analyses. In
fact p.M218V result to be benign because the SIFT score
was 1, Polyphen showed a score of 0.00. Similar results
were seen for p.N324S with Polyphen and SIFT scores of
0.00 and 0.38, respectively. Additional analyses in Muta-
tionTaster indicated that both variants behave as benign
polymorphisms.
Genetic screening of PTEN in the whole sample of
ASD-macrocephaly, either with or without epilepsy\EEG
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rozygous frameshift mutation (c.43delA; p.R15Dfs*9)
(Figure 1A) in one case with “extreme” macrocephaly,
autism, intellectual disability and history of a first unpro-
voked seizure. This boy was born at term, from non-
consanguineous parents, after uneventful pregnancy and
delivery. He experienced, since the first year, poor social
interaction and communication. Psychomotor develop-
ment was delayed and he walked without support atFigure 1 DNA sequence electropherograms showing the novel frame
alignment of the wild-type PTEN protein (in black) and the mutant pr30 months. At the age of 5 years and 9 months, he exhib-
ited a first generalized tonic-clonic seizure and underwent
valproic acid (VPA) treatment. When he came to our
attention, at the age of 6 years and 7 months, clinical
evaluation showed diffuse hypotonia, absence of speech,
moderate intellectual disability, severe behavior problems
(frustration intolerance, aggressive behaviors), stereotypies
and severe disorder of social interaction consistent with
DSM-IV-TR criteria for ASD. Head circumference wasshift mutation in PTEN (c.43delA, black arrowhead in A), and blast
otein (in red) (B).
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macrocephaly). He was still under VPA therapy, but he
had not experienced other seizures. Wake electroenceph-
alogram, brain MRI, karyotype, FRAXA and FRAXE ana-
lyses were normal.
The PTEN mutation detected in this boy determined
the replacement of eight amino acids (aa 15–22) with re-
spect to the canonical protein sequence and predicted
the introduction of an early stop codon with a severely
truncated protein (Figure 1B). The mutation was not
reported in the Kaviar2 database (http://db.systemsbiol-
ogy.net/kaviar/cgi-pub/Kaviar2.pl). Since parents refused
genetic testing, we could not determine whether the
variant was inherited or de novo.
Discussion
GlialCAM (glial cell adhesion molecule) is an Ig-like
protein of still poorly characterized function, possibly in-
volved in cell-matrix interactions and in cell motility
[28]. It is predominantly expressed at cell-cell contacts
between end-feet of astrocytes, and probably between
oligodendrocytes and astrocytes [22]. Disease-causing
mutations of GLIALCAM are associated with a pheno-
typic spectrum including macrocephaly, leukoencepha-
lopathy, and epilepsy, with or without autism, as well
as intellectual disability and psychomotor deterioration.
GlialCAM forms homo- and hetero-complexes that are
reduced by MLC-related mutations with ensuing defect-
ive trafficking to cell junctions [29]. GlialCAM has been
recently identified as a Cl− channel ClC-2 partner, tar-
geting it to cell junctions and modulating its conduct-
ance [30]. CLC-2 is a hyperpolarization-activated and
osmosensitive channel [31,32] possibly playing a role in
glial-mediated fluid and ion homeostasis, and in the
maintenance of low extracellular potassium during high
neuronal activity [30,33-35]. Analogously to Kir4.1 de-
fects, which predispose to autism-epilepsy comorbidity
by altering the astrocytic-dependent potassium buffering
[36], a defective ion trafficking due to GlialCAM mutations
might cause osmotic imbalance and fluid accumulation
[30,37,38] leading to the aforementioned macrocephalic-
related spectrum of diseases. Taken together, these evi-
dences led us to consider GLIALCAM as a candidate gene
in Autism-epilepsy associated with macrocephaly, and
to screen a sample of individuals with ASD either with
or without this comorbid endophenotype. Our negative
findings indicate a lack of clear association with autism,
macrocephaly and seizure susceptibility, although they
cannot completely rule out the involvement of GLIAL-
CAM in this endophenotype due to the relatively small
sample size. We cannot exclude, moreover, that Glial-
CAM may participate in a more complex glial protein
network, contributing to dysregulation of astrocyte
homeostasis and cell growth in AEP.Finally, we also found a novel PTEN frameshift muta-
tion in one patient with AEP associated with extreme
macrocephaly. Mutations in PTEN have already been as-
sociated with the development of many cancers as well
as non-tumor phenotypes, including macrocephaly and
ASD [19,39,40]. PTEN is an important negative regulator
of PI3K/AKT/mTOR signaling pathway, which has
roles in controlling cell growth, survival and prolifera-
tion [41,42]. Mutations in genes of this pathway have
been associated with other conditions encompassing
epilepsy and/or ASD, such as the Tuberous Sclerosis
complex [43] and other megalencephaly syndromes
[44,45], suggesting that disinhibited PTEN/PI3K/AKT/
mTOR signaling may represent a key mechanism impli-
cated in the pathogenesis of ASD, seizures and brain
overgrowth. Mice with targeted inactivation of the Pten
gene in differentiated neurons of the cerebral cortex
and hippocampus also demonstrated macrocephaly,
abnormal social interaction and exaggerated responses
to sensory stimuli [46]. Ablating Pten broadly during
developmental stages causes premature death in mice,
often accompanied by severe epileptic activity [20]. Al-
though we found a single patient harboring a PTEN mu-
tation, this gene remains a likely candidate in AEP with
extreme macrocephaly.Conclusions
We did not find a clear pathogenic link between GLIAL-
CAM variants and AEP-macrocephaly comorbidity, sug-
gesting that GLIALCAM genetic screening is currently
not indicated in patients with ASD. However, the rela-
tively small size of our sample prevents to draw defini-
tive conclusions. Although next-generation sequencing
techniques offer enormous opportunities to discover the
genetic background of autism-related disorders, their
extreme phenotypic heterogeneity and the difficulty in
recruiting pathophysiologically homogeneous samples,
make it difficult to establish actual causative correla-
tions. A candidate-gene approach, although less per-
forming, could potentially be applicable when justified
by a clear clinical and/or pathophysiological rationale.
Working on clinical endophenotypes might help - in
both approaches - to define more valid genotype-
phenotype correlations. One example is, in this work,
the identification of a deleterious mutation of PTEN in a
patient with “extreme” macrocephaly, in one out of 6
cases with this somatic endophenotype. The concur-
rence of epilepsy in the same patient also suggests that
PTEN gene, and the downstream PI3K/AKT/mTOR
pathway, deserves to be further investigated in autism-
epilepsy comorbidity. Accurate definition of clinical
endophenotypes might be an approach to untangle the
complex genotype-phenotype correlations in AEP.
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